Carfilzomib launch time in China

On Year7Month8Day, Carfilzomib (Carfilzomib) has been approved for marketing in China. Carfilzomib is a targeted therapy drug used to treat multiple myeloma (Multiple Myeloma) and other related blood cancers and is widely used around the world.

Carfilzomib has been launched in China and is included in medical insurance. Patients can purchase it domestically at a price of around 8,000 to 9,000 yuan. Please consult the local hospital pharmacy for specific prices. In foreign countries, the original drug of carfilzomib is mainly available, and the cheaper version is the European version of the original drug, which costs around 5,000. And the medicinal ingredients and efficacy are the same as those of domestic original medicines.

In China, drug marketing requires approval from the national drug regulatory authorities, which usually includes the approval process of the National Medical Products Administration of China (NMPA). Carfilzomib has gone through relevant clinical trials and approval processes and has been approved for sale and use in the Chinese market.

The launch of carfilzomib provides a new treatment option for multiple myeloma patients in China and is expected to improve the survival and quality of life of patients. The introduction of this drug has had a positive impact on China's medical community and patients, providing more opportunities for effective treatment.

It should be noted that the availability and use of drugs may be subject to the doctor's prescription, the patient's specific condition, medical insurance and other factors. Therefore, if you or someone you know requires treatment with carfilzomib or other medications, you should consult a doctor or medical professional for detailed information about use, dosage, and treatment plans. In addition, the marketing status and availability of drugs may change over time, so it is recommended to consult the latest pharmaceutical information and government approval documents for the most accurate information.